Login to Your Account

Proqr Therapeutics spins out Amylon to focus on rare beta amyloid disorders

By Cormac Sheridan
Staff Writer

Tuesday, September 12, 2017

DUBLIN – Proqr Therapeutics NV has spun out a startup firm, Amylon Therapeutics NV, to take forward an RNA-based drug development program focused on rare beta-amyloid-related disorders.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription